CAU
BMRN icon

Caxton Associates (UK)’s BioMarin Pharmaceuticals BMRN Stock Holding History

Caxton Associates (UK)’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-49,308
Closed -$2.79M – 768
2026
Q1 		$2.79M Sell
49,308
-103,444
-68% -$6.03M 0.06% 143
2025
Q4 		$9.08M Buy
+152,752
New +$8.32M 0.18% 48
2025
Q3 		– Sell
-6,174
Closed -$339K – 718
2025
Q2 		$339K Buy
+6,174
New +$364K 0.01% 514

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Caxton Associates (UK)'s BMRN Position: Q2 2026 in Review

Caxton Associates (UK) sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 49,308 shares — an estimated $2.79M sold.

Caxton Associates (UK) first reported a position in BMRN in Q2 2025 and held it in 3 quarters. The position peaked at $9.08M in Q4 2025. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Caxton Associates (UK) reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Caxton Associates (UK) sold 49,308 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $2.79M.
  • Caxton Associates (UK) first reported a position in BioMarin Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • Caxton Associates (UK)'s BioMarin Pharmaceuticals position peaked at $9.08M in Q4 2025.
  • 564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Caxton Associates (UK)'s 13F filing for Q2 2026, filed 14 Aug 2026.